Development of novel vaccines using DNA shuffling and screening strategies.
DNA shuffling and screening technologies recombine and evolve genes in vitro to rapidly obtain molecules with improved biological activity and fitness. In this way, genes from related strains are bred like plants or livestock and their successive progeny are selected. These technologies have also been called molecular breeding-directed molecular evolution. Recent developments in bioinformatics-assisted computer programs have facilitated the design, synthesis and analysis of DNA shuffled libraries of chimeric molecules. New applications in vaccine development are among the key features of DNA shuffling and screening technologies because genes from several strains or antigenic variants of pathogens can be recombined to create novel molecules capable of inducing immune responses that protect against infections by multiple strains of pathogens. In addition, molecules such as co-stimulatory molecules and cytokines have been evolved to have improved T-cell proliferation and cytokine production compared with the wild-type human molecules. These molecules can be used to immunomodulate vaccine responsiveness and have multiple applications in infectious diseases, cancer, allergy and autoimmunity. Moreover, DNA shuffling and screening technologies can facilitate process development of vaccine manufacturing through increased expression of recombinant polypeptides and viruses. Therefore, DNA shuffling and screening technologies can overcome some of the challenges that vaccine development currently faces.
Locher
Christopher P
CP
Maxygen Inc, Division of Infectious Diseases, 200 Penobscot Drive, Redwood City, CA 94063, USA. christopher.locher@maxygen.com
Soong
Nay Wei
NW
Whalen
Robert G
RG
Punnonen
Juha
J
D000818:Animals; D019295:Computational Biology; D004247:DNA / Q000235:genetics*; D032621:DNA Shuffling; D019020:Directed Molecular Evolution; D005818:Genetic Engineering / Q000379:methods; D015316:Genetic Therapy; D006801:Humans; D008403:Mass Screening; D011993:Recombinant Fusion Proteins / Q000276:immunology; D011995:Recombination, Genetic; D019444:Vaccines, DNA / Q000235:genetics* / Q000276:immunology; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology; D014780:Viruses / Q000235:genetics / Q000276:immunology
D011993:Recombinant Fusion Proteins; D019444:Vaccines, DNA; D014765:Viral Vaccines; D004247:DNA